title: Current status and future perspectives of immunotherapy in Latin America and Cuba.
abstract: Most Latin-American countries use subcutaneous immunotherapy (SCIT) extracts from the United States and Europe and sublingual immunotherapy (SLIT) from Europe, with the exception of Argentina, Brazil, Cuba and Mexico. The number of researches on immunotherapy (IT) in Latin America has increased extensively in the last years. Only few Latin American countries have their own guidelines on IT, and, in general, the economic resources for medical research on IT are still low in the area. A global approach for the future of IT in Latin America includes to improve standardization, quality control and the production of allergen products, to develop IT guidelines and clinical investigation by the highest number of countries, to improve the regulatory status for allergens products in the area, and to expand IT accessibility for low-income patients. In Cuba, the first registered allergen vaccines were developed and registered in 2006: a standardized (in biologic units) and freeze dried product for SCIT, with a sublingual version developed in 2009. As much as 23.000 IT treatments were applied in 2011, all provided to patients free of charge. In 2012, Cuban researchers developed an IT vaccine with adjuvant for subcutaneous route, which uses Neisseria meningitidis proteoliposome as an adjuvant, added to the purified Dermatophagoides siboney major allergens: Der s1 and Der s2. Since December 2012, this vaccine is in Phase I clinical trial, evaluating its safety, tolerability and immunogenicity in asthmatic patients sensitized to this allergen. Cuban perspectives on IT includes to work on new indications for IT, to investigate the preventive effect and cost-effectiveness for the current vaccines, to develop new products with mixed formulas of house dust mites for SLIT, to complete the phase I and II clinical study for dust mite plus adjuvant vaccine, to develop allergen vaccines for fungi allergy and to complete the Cuban guideline for allergen IT management.
authors.affiliation: Medical Center: José Manuel Seguí, Artemisa, Cuba.
authors.forename: Alexander
authors.initials: A
authors.lastname: Diaz Rodriguez
authors.affiliation: National Center of Bioproducts, BioCen, Mayabeque, Cuba.
authors.forename: Alexis Labrada
authors.initials: AL
authors.lastname: Rosado
authors.affiliation: National Center of Bioproducts, BioCen, Mayabeque, Cuba.
authors.forename: Raúl Lázaro Castro
authors.initials: RL
authors.lastname: Almarales
authors.affiliation: University Hospital ¨General Calixto García¨, Havana, Cuba.
authors.forename: Mirta Álvarez
authors.initials: MÁ
authors.lastname: Castelló
keywords: Cuba; Immunotherapy; Latin America
references.citation: Rev Alerg Mex. 2012 Jul-Sep;59(3):148-54
references.pmid: 24007991
references.citation: Ann Allergy Asthma Immunol. 2003 Jun;90(6):664-8
references.pmid: 12839327
references.citation: Vaccine. 2006 Apr 12;24 Suppl 2:S2-36-7
references.pmid: 16823917
references.citation: J Investig Allergol Clin Immunol. 1995 Jan-Feb;5(1):18-24
references.pmid: 7551200
references.citation: J Investig Allergol Clin Immunol. 1993 Sep-Oct;3(5):245-9
references.pmid: 8298748
references.citation: Rev Alerg Mex. 2010 Mar-Apr;57(2):57-9
references.pmid: 20857631
references.citation: Rev Alerg Mex. 2009 May-Jun;56(3):80-5
references.pmid: 19623784
references.citation: J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558-62
references.pmid: 9802362
references.citation: Rev Alerg Mex. 2008 Jan-Feb;55(1):33-7
references.pmid: 18697451
references.citation: Clin Transl Allergy. 2014 Jun 04;4:20
references.pmid: 24976949
references.citation: J Evid Based Med. 2011;4(3):161-4
references.pmid: 21894615
references.citation: Rev Med Chil. 2007 Dec;135(12):1566-71
references.pmid: 18357358
references.citation: J Investig Allergol Clin Immunol. 2005;15(3):189-96
references.pmid: 16261955
references.citation: J Investig Allergol Clin Immunol. 2010;20(4):311-23
references.pmid: 20815309
references.citation: Immunotherapy. 2009 Mar;1(2):177-9
references.pmid: 20635938
references.citation: Rev Alerg Mex. 2010 Jan-Feb;57(1):3-10
references.pmid: 20857623
references.citation: World Allergy Organ J. 2009 Nov;2(11):233-81
references.pmid: 23268425
references.citation: Allergy. 2004 Nov;59(11):1161-4
references.pmid: 15461595
references.citation: Rev Alerg Mex. 2012 Jul-Sep;59(3):139-47
references.pmid: 24007990
references.citation: Rev Alerg Mex. 2001 Mar-Apr;48(2):45-7
references.pmid: 11421174
references.citation: Cochrane Database Syst Rev. 2010 Aug 04;(8):CD001186
references.pmid: 20687065
references.citation: Ann Allergy Asthma Immunol. 2013 Nov;111(5):415-419.e1
references.pmid: 24125151
references.citation: Rev Alerg Mex. 2009 Mar-Apr;56(2):31-5
references.pmid: 19526951